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INTRODUCTION
Fragile X syndrome (FXS) is a triplet-repeat 
expansion disorder of the X chromosome, 
with repeats of more than 200 (sometimes 
referred to as the full mutation) causing 
FXS and ~59–200 repeats (the so-called 
premutation) being responsible for a 
variety of clinical presentations. Clinicians 
in primary care should be aware of these 
conditions and in particular be vigilant for 
common comorbidities to allow for early 
treatment. This article summarises the 
common issues for individuals with FXS 
and carriers of the premutation.
HOW ARE INDIVIDUALS WITH FRAGILE X 
SYNDROME TYPICALLY AFFECTED?
FXS is the most common inherited cause 
of intellectual disability, occurring in 
approximately 1 in 3000–4000 males and 
1 in 6000–8000 females. Although the 
genetic underpinnings of FXS are similar 
across individuals, the manifestations vary 
widely and in some ways there is no ‘typical’ 
presentation. Nonetheless, males with the 
syndrome generally have an intellectual 
disability ranging from mild to severe, 
whereas females are much more variably 
affected (due to random X-inactivation) 
and can range from being essentially 
asymptomatic to having a severe intellectual 
disability. There are a number of common 
physical comorbidities associated with the 
syndrome including epilepsy (~25%), mitral 
valve prolapse (≤80%), hyperextensible joints, 
and an increased risk of inguinal hernias. 
Anxiety, attention deficit hyperactivity disorder 
(ADHD), and autism spectrum disorders 
(ASDs) are also significantly more common. 
Hyperarousal and sensory hypersensitivity 
are frequent symptoms, which may occur 
across a range of diagnoses. It is worth 
noting that, although one-third to two-thirds 
of individuals with FXS may meet criteria 
for an ASD, the presentation often varies 
subtly from that seen in idiopathic ASDs. 
In particular, some traits such as social 
difficulties and atypical eye contact may 
have very different underpinnings in FXS as 
compared with ASDs.1
WHAT INTERVENTIONS ARE 
RECOMMENDED IN FRAGILE X 
SYNDROME?
To date there is no medication specifically 
for core FXS symptoms (although this is 
an active area of clinical trial research). 
However, active vigilance in primary care is 
recommended for common comorbidities, 
which often impact quality of life most. 
Particularly, epilepsy, anxiety, and ADHD 
are common in individuals with FXS,2 
and active treatment for these should 
be considered. As ever, clinicians should 
be aware of the possibility of diagnostic 
overshadowing, meaning that treatable 
comorbidities may go untreated if 
attributed to core FXS symptomatology. 
The Royal College of General Practitioners’ 
syndrome-specific medical health check 
guide for FXS provides further details on 
common comorbidities to be routinely 
reviewed in primary care.3 Where necessary, 
referral to the local community learning 
disability team should be considered to 
support optimal diagnosis and treatment 
(Box 1). Multidisciplinary assessment is 
key, particularly occupational therapy 
for functional and sensory assessment, 
and speech and language therapy for 
communication support. Many families find 
the support of specific fragile X support 
organisations to be of help; the Fragile X 
Society (https://www.fragilex.org.uk/) being 
the UK-based organisation for this.
HOW ARE CARRIERS OF THE FMR1 
PREMUTATION TYPICALLY AFFECTED?
The FMR1 premutation is carried by up 
to 1 in 150 females and 1 in 470 males. 
Historically, carriage of the FMR1 
premutation (which is found in families 
with FXS) was not thought to be associated 
with any morbidity. However, more 
recently it has become apparent that it 
brings with it the increased likelihood of 
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a number of conditions, notably including 
fragile X-associated premature ovarian 
insufficiency (FXPOI), fragile X-associated 
tremor and ataxia syndrome (FXTAS), and 
higher rates of mood and anxiety disorders.
Fragile X premature ovarian insufficiency 
(FXPOI) affects approximately 20% of 
female premutation carriers with increased 
infertility, and menopause occurring on 
average 5 years early.5 A small proportion 
of women will experience the menopause 
at a much earlier stage, in their 20s or 30s. 
Notably, women with the full mutation do 
not, however, experience FXPOI.
Approximately 45% of males and ≤16% 
of females carrying an FMR1 premutation 
develop fragile X-associated tremor-ataxia 
syndrome (FXTAS). This neurodegenerative 
condition usually occurs over the age of 
50 with risk of manifestation and severity 
increasing with age. Apart from the core 
symptoms of action tremor and/or 
ataxia (gait difficulties and disturbed limb 
coordination in particular), it may present 
with mild Parkinsonism, cognitive decline 
(short-term memory and executive function 
deficits), neuropathy, neuropathic pain, 
and autonomic dysfunction. Regarding the 
treatment of FXTAS, referral to neurology 
should be considered, where symptomatic 
treatments for action tremor, Parkinsonism, 
neuropathic pain, and mood/anxiety 
problems may have a role. One small trial 
of memantine for cognitive effects showed 
no effect, although there may be a role for 
cholinesterase inhibitors. As with the general 
population, treatment of contributing factors 
including hypothyroidism, vitamin B12 
and folate deficiency, and cerebrovascular 
risk should be considered. Long-term 
care of FXTAS is complex and requires a 
multidisciplinary approach.
Studies of premutation carriers report a 
broad range of other medical problems,6 
commonly including thyroid problems and 
mood and anxiety disorders. These should 
be treated as they would be in the general 
population, acknowledging the additional 
stressors associated with providing care 
for someone with special needs. As is the 
case for anxiety and mood disorders in 
the general population, clinicians need to 
take particular care not to attribute valid 
concerns, for example, about a child, to 
symptoms of psychiatric disorder.
WHAT ARE THE IMPLICATIONS FOR 
FAMILY PLANNING?
Typically, the expansion from premutation 
to full mutation occurs during maternal 
meiosis; whereas female premutation 
carriers may experience expansion to 
a full mutation in their children, male 
carriers usually pass on the premutation 
unchanged. The birth of a child with FXS 
is often the first indication that the family 
carries the fragile X premutation, and 
thus there are implications for both the 
immediate and wider family.
For the mother with a child with FXS 
already, there will be a high chance that 
the premutation will expand again in future 
pregnancies; children inheriting the faulty 
gene (1 in 2) are likely to have full-mutation 
FXS. When members of the extended family 
are identified as carrying the premutation 
but who do not have children with FXS, the 
likelihood of expansion into the full mutation 
is more variable, depending on a number 
of factors including specific premutation 
repeat length in the premutation carrier 
(the risk of expansion is increased with 
increasing length). Similarly, for those 
with premutations identified in other 
screening programmes, the risk of the 
repeat expanding is more variable. Contact 
with genetic counselling will be helpful to 
consider all available options for family 
planning, which for some may include 
prenatal testing or preimplantation genetic 
diagnosis. This can quite understandably 
be a very stressful time for families and a 
cause of considerable strain.
Where an individual is identified as 
carrying the premutation through extended 
family screening, this brings its own specific 
issues and potential stresses, for example, 
not only the news that a woman may have 
an affected child but also the finding that 
ovarian reserve may be reduced because 
of FXPOI leading to difficulty in achieving a 
pregnancy.
CONCLUSION
Changes in the FMR1 gene are not only 
associated with both the fragile X syndrome, 
but also with a wide range of clinical 
manifestations in family members carrying 
the premutation. Clinicians are advised to be 
vigilant for common comorbidities, allowing 
early diagnosis, referral, and treatment. 
The familial nature of these conditions is of 
importance to general practice.
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Box 1. Genetic diagnosis in 
intellectual disability
•  Seeking a genetic diagnosis for an 
intellectual disability is standard care in 
paediatric services, although there are large 
numbers (especially of adults) who have 
either never had genetic testing or for whom 
it was so long ago so as to be of limited 
meaning.
•  It is estimated that routine genetic testing 
in individuals with intellectual disability can 
identify a genetic cause in up to 20%, with 
more detailed sequencing (not yet routinely 
available outside research studies) taking this 
up to over 50%.4
•  Genetic testing should ideally be a routine 
part of care and should be considered where 
it has not been done previously. Clinicians 
should discuss with their local genetics 
department and community learning 
disability team to establish local practices.
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